Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting

Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)

Read more at prnewswire.com